- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06416709
Stem Cell Treatment for Lung Injury Caused by Major Infectious Diseases
To Study the Clinical Treatment Plan of Lung Injury Caused by Major Infectious Diseases Treated With Stem Cells
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Zhe Xu, Dr
- Phone Number: 86 150 0111 1836
- Email: xuzhe302@139.com
Study Locations
-
-
-
Beijing, China
- Recruiting
- Beijing 302 Hospital
-
Contact:
- Fu-Sheng Wang, Doctor
- Phone Number: 8610-13671005510
- Email: fswang302@163.com
-
Principal Investigator:
- Fu-Sheng Wang, Doctor
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥18 years old;
- Understand and sign the informed consent form, comply with the relevant requirements of this study, and agree not to participate in other studies and not to receive other immunotherapy during the study participation;
meet the diagnosis of viral pneumonia and are in the advanced stage of disease: (1)The etiological diagnosis met any of the following criteria:
①Sars-cov-2 infection: Respiratory specimens (nasal/throat swabs or bronchial secretions/bronchoalveolar lavage fluid) were positive for Sars-cov-2 nucleic acid and/or antigen within 14 days;
②Adenovirus infection: positive for adenovirus nucleic acid and/or antigen in respiratory secretions or blood within 14 days;
③Influenza virus infection: positive respiratory secretions or blood for influenza virus nucleic acid and/or antigen within 14 days;
④Other respiratory virus antigens or nucleic acids were positive in respiratory secretions or blood within 14 days; (2)Imaging manifestations: chest X-ray or CT was consistent with the imaging features of viral pneumonia, manifested as multiple patchy shadows, ground glass shadows or consolidation in both lungs; (3)Respiratory System Indicators:Respiratory distress, respiratory rate (RR) ≥30 breaths/min at rest; In the resting state, oxygen saturation of finger pulse was ≤93% while breathing air; Oxygen and index (partial pressure of arterial oxygen/fraction of inspired oxygen) ≤300mmHg and > 200mmHg;
- Invasive mechanical ventilation and vasopressor medications were not required.
Exclusion Criteria:
- Patients tested active for HBV, HCV, HIV, or tuberculosis at the time of screening;
- patients with solid tumors, leukemia or mental disorders;
- The peripheral white blood cell count was still more than 12×109/L or less than 4×109/L after effective anti-infective treatment. Plasma C-reactive protein >2 times the upper limit of normal; Plasma procalcitonin >2 times the upper limit of normal;
- There were severe complications or major organ complications: severe cardiovascular and cerebrovascular diseases: acute heart failure NYHAⅢ; uncontrolled myocarditis or valvular disease; malignant arrhythmia; incident (≤6 months) cardio-cerebrovascular events (myocardial infarction or stroke); previous chronic bronchitis, severe asthma, obstructive pulmonary emphysema, pulmonary fibrosis, and other diseases that require long-term oxygen therapy or affect daily activities; patients with acute renal failure (≥44.2 μmol/L daily increase in serum creatinine) or chronic renal insufficiency had serum creatinine ≥442 μmol/L; the liver function was markedly abnormal and ALT≥5×ULN; serum TBil≥10×ULN or daily increase ≥17.1 μmol/L; signs of bleeding, PTA≤ 40% (or INR≥1.5); severe anemia (Hb<60g/L), moderate or severe thrombocytopenia (PLT<60×109/L), and DIC; other conditions that the investigators thought might affect treatment effectiveness.
- Unwillingness to sign informed consent forms;
- Evidence of drug addiction within 6 months before trial entry;
- Patients who are currently enrolled in other clinical trials and may violate this treatment regimen and observation indicators;
- Unable or unwilling to provide informed consent or to comply with the study requirements;
- Other serious conditions that may preclude the clinical trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: placebo control use saline
saline is used as placebo in the placebo comparator group
|
10 ml saline is used as placebo once every three days and for three times
|
Experimental: mesenchymal stem cells treatment
Mesenchymal stem cell dose is 5×10*7/10ml and is transplanted by intravenous infusion.
The cells are used once every three days and for three times.
|
Mesenchymal stem cell dose is 5×10*7/10ml and is transplanted by intravenous infusion.
The cells are used once every three days and for three times
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with side effects in MSCs treatment groups
Time Frame: 48 weeks
|
Investiagte the number of participants with treatment-related adverse events as assessed by CTCAE v4.0 after MSCs infusion.
|
48 weeks
|
High-resolution CT imaging
Time Frame: 2 weeks
|
at week 2, evaluate high-resolution CT imaging changes in lung lesions and compare with baseline
|
2 weeks
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Fu sheng Wang, Dr, Beijing 302 Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- KY-2023-2-6-2
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lung Injury
-
Kocaeli UniversityCompletedVentilator-Induced Lung Injury | Ventilator Adverse Event | Lung Injury, AcuteTurkey
-
Virginia Commonwealth UniversityCompletedCOVID-19 | Kidney Injury | Lung Injury, AcuteUnited States
-
Yangzhou UniversityCompleted
-
Taipei Medical University WanFang HospitalUnknown
-
University of PittsburghNational Heart, Lung, and Blood Institute (NHLBI)RecruitingElectronic Cigarette Use | Acute Lung Injury | Pulmonary Injury | Electronic Cigarette Related Lung InjuryUnited States
-
Changhai HospitalCompletedAcute Lung Injury | Single Nucleotide Polymorphism | Kidney InjuryChina
-
Damanhour UniversityAlexandria UniversityCompletedAcute Lung Injury, Transfusion RelatedEgypt
-
Xinhua Hospital, Shanghai Jiao Tong University...RecruitingVentilator-Induced Lung InjuryChina
-
Ayse UlgeyNot yet recruitingVentilator-induced Lung InjuryTurkey
-
GlaxoSmithKlineCompleted
Clinical Trials on saline
-
Vanderbilt University Medical CenterActive, not recruitingPostural Tachycardia SyndromeUnited States
-
Johns Hopkins UniversityCystic Fibrosis FoundationCompletedCystic Fibrosis
-
University Hospital Inselspital, BerneCompletedCardiovascular Diseases | Valvular Heart DiseaseSwitzerland
-
Aalborg UniversityThe Danish Rheumatism AssociationCompleted
-
Imam Abdulrahman Bin Faisal UniversityUnknownOtorhinolaryngologic Diseases | RhinosinusitisSaudi Arabia
-
Dr. Michael FlavinWithdrawn
-
Qassim UniversityCompletedApical Periodontitis | Post Operative Pain | Dental Pulp NecrosesSaudi Arabia
-
Szpital im. Św. Jadwigi ŚląskiejRecruiting
-
Makassed General HospitalCompletedLength of Hospital StayLebanon
-
University of Washington, the Collaborative Health...Cystic Fibrosis FoundationCompleted